MEDCX | REBAX | MEDCX / REBAX | |
Total Expense Ratio | 1.81 | 1.13 | 160% |
Annual Report Gross Expense Ratio | 1.82 | 1.13 | 161% |
Fund Existence | 23 years | 19 years | - |
Gain YTD | 1.169 | 2.334 | 50% |
Front Load | N/A | 5% | - |
Min. Initial Investment | 1000 | 2000 | 50% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 6.99B | 279M | 2,506% |
Annual Yield % from dividends | 5.77 | 5.16 | 112% |
Returns for 1 year | 5.43 | 6.37 | 85% |
Returns for 3 years | 16.47 | 18.21 | 90% |
Returns for 5 years | 7.77 | 11.60 | 67% |
Returns for 10 years | 21.43 | 28.38 | 76% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
OIGAX | 34.73 | N/A | N/A |
Invesco Oppenheimer International Gr A | |||
FICGX | 12.17 | N/A | N/A |
Cantor Fitzgerald Large Cap Fcs Cl A | |||
BMCRX | 24.67 | N/A | N/A |
BlackRock Advantage Large Cap Gr R | |||
TNVRX | 16.12 | N/A | N/A |
1290 GAMCO Small/Mid Cap Value R | |||
EMWLX | 17.34 | N/A | N/A |
Lord Abbett Emerging Markets Equity R6 |